To view this email as a web page, click here.
 
HIGHLIGHTS   |  October 19, 2019
 
Study Moves the Needle for Melanoma Patients with Rare BRAF Mutations
BRAF and MEK inhibitors appear to have clinical activity in patients with metastatic melanoma with rare BRAF mutations.
Read more
 
 
FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer
The agency is set to make a decision on the investigational antibody drug conjugate by the first quarter of 2020.
Read more
 
 
IN CASE YOU MISSED IT
 
Bioinformatics Analysis Identifies Key Biomarkers
COX7RP contributes to endometrial and breast cancer growth.
Read more
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.